Professor | Shi-Lin Xu | Asia Growth Partners

Name	Shi-Lin Xu
Contact Information	slxu@simm.ac.cn
Language ability	Chinese, English
Province	Shanghai

Name

Shi-Lin Xu

Contact Information

slxu@simm.ac.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Medical School
Academic Background & Achievements	2009-09 to 2014-07 PhD: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences 2005-09 to 2009-07 Bachelor's: Nanchang University
Work Experience	2019-09 to Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher 2014-11 to 2019-09 - University of Michigan - Postdoctoral Researcher 2009-09 to 2014-07 - Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences - PhD Student 2005-09 to 2009-07 - Nanchang University - Undergraduate

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Medical School

Academic Background & Achievements

2009-09 to 2014-07 PhD: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
2005-09 to 2009-07 Bachelor's: Nanchang University

Work Experience

2019-09 to Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
2014-11 to 2019-09 - University of Michigan - Postdoctoral Researcher
2009-09 to 2014-07 - Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences - PhD Student
2005-09 to 2009-07 - Nanchang University - Undergraduate

Areas of Focus	Development of small molecule anti-tumor drugs
Publications	Discovery of a PROTAC degrader for METTL3-METTL14 complex, 13th Author, 2024 Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor, 11th Author, 2024 Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy, 9th Author, 2023 Discovery of 7H-Pyrrolo2,3-dpyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors, 10th Author, 2023 Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase, 11th Author, 2022 Structure-Based of a Series of NSD2-PWWP1 Inhibitors, 11th Author, 2022 Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression, 3rd Author, 2021 Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation, 10th Author, 2021 Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation, 7th Author, 2021 Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor, 11th Author, 2021 Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity, 1st Author, 2020 Structure-based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction, 4th Author, 2019 Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases, 2nd Author, 2019 Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction, 1st Author, 2018 Design and optimization of small molecule inhibitors blocking the menin-MLL interaction, 2nd Author, 2017 Structure-based design of small-molecular inhibitors targeting the Menin-MLL protein-protein interaction, 1st Author, 2017 1-Benzyl-4-phenyl-1H-1,2,3-triazoles improve the transcriptional functions of estrogen-related receptor gamma and promote the browning of white adipose, 1st Author, 2015 Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido4,5-dpyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties, 1st Author, 2013 Pyrimido4,5-dpyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine(790) to Methionine(790) (T790M) Mutants, 3rd Author, 2013 1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor alpha, 1st Author, 2013 Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine(790) -> methionine(790) mutant, 1st Author, 2012 Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine(790) -> Methionine(790) Mutant, 3rd Author, 2012

Areas of Focus

Development of small molecule anti-tumor drugs

Publications

Discovery of a PROTAC degrader for METTL3-METTL14 complex, 13th Author, 2024
Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor, 11th Author, 2024
Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy, 9th Author, 2023
Discovery of 7H-Pyrrolo2,3-dpyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors, 10th Author, 2023
Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase, 11th Author, 2022
Structure-Based of a Series of NSD2-PWWP1 Inhibitors, 11th Author, 2022
Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression, 3rd Author, 2021
Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation, 10th Author, 2021
Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation, 7th Author, 2021
Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor, 11th Author, 2021
Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity, 1st Author, 2020
Structure-based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction, 4th Author, 2019
Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases, 2nd Author, 2019
Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction, 1st Author, 2018
Design and optimization of small molecule inhibitors blocking the menin-MLL interaction, 2nd Author, 2017
Structure-based design of small-molecular inhibitors targeting the Menin-MLL protein-protein interaction, 1st Author, 2017
1-Benzyl-4-phenyl-1H-1,2,3-triazoles improve the transcriptional functions of estrogen-related receptor gamma and promote the browning of white adipose, 1st Author, 2015
Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido4,5-dpyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties, 1st Author, 2013
Pyrimido4,5-dpyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine(790) to Methionine(790) (T790M) Mutants, 3rd Author, 2013
1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor alpha, 1st Author, 2013
Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine(790) -> methionine(790) mutant, 1st Author, 2012
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine(790) -> Methionine(790) Mutant, 3rd Author, 2012

Anti-Tumor Small Molecule Drug Development Cancer Chemistry Pharmacology Biomedicine Oncology Medicinal Chemistry Therapeutics

Kui Hong - Wuhan University

Wenhu Duan - University of Chinese Academy of Sciences

Jinxue He - University of Chinese Academy of Sciences

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us